| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 107.3 | 256.5 | 103.9 |
| Other income | 0.4 | 0.1 | 0.2 |
| Total income | 107.6 | 256.5 | 104.2 |
| Profit before exceptional items & tax | 4.2 | 5.5 | -0.6 |
| Profit before tax | 4.2 | 5.5 | -0.6 |
| Net profit | 3.0 | 4.2 | -0.5 |
| Operating margin | 3.9% | 2.1% | -0.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | -28.60% |
|---|---|
| Revenue, year on year | +3.30% |
NSE results filing, NSE: ARISTO. Figures extracted from the filing.
Aristo Bio-Tech and Lifescience Ltd: key numbers
- Share price
- ₹94.00
- Market cap
- ₹63.99 Cr
- Revenue (annual)
- ₹363.7 Cr
- Net profit (annual)
- ₹7.18 Cr
- P/E (TTM)
- 8.9×Sector 37.2×
- Promoter holding
- 73.42%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aristo Bio-Tech and Lifescience Ltd
All →Aristo Bio-Tech and Lifescience Other Announcement
Aristo Bio-Tech sent a Reg 36(1)(b) web-link letter for its FY 2025-26 Annual Report to shareholders without email IDs. No financial or business event is disclosed.
Aristo Bio-Tech and Lifescience Annual General Meeting
Aristo Bio-Tech and Lifescience Limited has issued a notice for its 21st Annual General Meeting to be held on September 30, 2026.
Aristo Bio-Tech and Lifescience Board Meeting Outcome
Aristo Bio-Tech declared a final dividend of Rs. 0.60 per share and approved re-appointments for directors and the cost auditor.
Aristo Bio-Tech and Lifescience Financial Results
Aristo Bio-Tech approved audited FY26 financial results and recommended a final dividend of ₹0.60 per share. The results showed strong annual performance with unmodified audit opinions.
Aristo Bio-Tech and Lifescience Other Announcement
Aristo Bio-Tech submitted its annual SDD compliance certificate for FY 2025-26. The certificate confirms maintenance of the mandatory structured digital database for insider trading monitoring.
Aristo Bio-Tech and Lifescience Board Meeting Date
Aristo Bio-Tech scheduled a board meeting for May 29, 2026, to consider audited FY26 results and a final dividend. Trading remains closed until May 31.